Products for Research Use Only
RegisterLogin

Pirfenidone

CAT: 0804-HY-B0673-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0673-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].
CAS Number
53179-13-8
Product Name Alternative
AMR69
UNSPSC
12352005
Hazard Statement
H302
Target
CCR; TGF-beta/Smad
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Pirfenidone.html
Purity
99.99
Solubility
DMSO : ≥ 100 mg/mL|H2O : 12.5 mg/mL (ultrasonic)
Smiles
O=C1C=CC(C)=CN1C2=CC=CC=C2
Molecular Formula
C12H11NO
Molecular Weight
185.23
Precautions
H302
References & Citations
[1]Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354 (2) :542-7.|[2]Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446 (1-3) :177-85.|[3]Yang Y, et al. Inhibition of Pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transitionof human lens epithelial cells line SRA01/04. PLoS One. 2013;8 (2) :e56837.|[4]Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16.|[5]Brooks D, et al. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 2018 May 4;9 (34) :23462-23481.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
B2288-5.1Pirfenidone

Popular Products